20,300 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by Erste Asset Management GmbH

Erste Asset Management GmbH purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 20,300 shares of the biotechnology company’s stock, valued at approximately $2,936,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Acuta Capital Partners LLC bought a new stake in Ascendis Pharma A/S in the third quarter valued at about $3,136,000. Finepoint Capital LP boosted its holdings in Ascendis Pharma A/S by 0.4% during the third quarter. Finepoint Capital LP now owns 190,072 shares of the biotechnology company’s stock valued at $28,380,000 after purchasing an additional 800 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Ascendis Pharma A/S by 49.5% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 71,307 shares of the biotechnology company’s stock valued at $10,647,000 after purchasing an additional 23,595 shares during the period. Loomis Sayles & Co. L P raised its holdings in shares of Ascendis Pharma A/S by 35.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after buying an additional 48,120 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its position in shares of Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after buying an additional 170,942 shares during the period.

Ascendis Pharma A/S Trading Down 1.9 %

Shares of NASDAQ ASND opened at $133.51 on Tuesday. Ascendis Pharma A/S has a 1 year low of $101.43 and a 1 year high of $161.00. The firm’s 50-day moving average is $131.91 and its 200-day moving average is $132.38. The firm has a market capitalization of $8.10 billion, a PE ratio of -16.52 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -7.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ASND. Wells Fargo & Company increased their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Jefferies Financial Group lifted their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. JPMorgan Chase & Co. reduced their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. Wedbush reiterated an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Bank of America increased their price target on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.